ArticleEuropean journal of nuclear medicine and molecular imaging2024
Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy.
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 7 citations in OpenAlex.
- PreclinicalJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Review
- Salivary glands as the primary dose-limiting organ: an integrated dosimetry, efficacy, and toxicity study ofFrontiers in pharmacology · 2026Article
- Targeting lipocalin-2 in atherosclerosis: biological functions, pathogenic mechanisms, and therapeutic potential.Frontiers in cardiovascular medicine · 2026Review
- Anti-Breast Cancer Properties and In Vivo Safety Profile of a Bis-Carbazole Derivative.Pharmaceutics · 2025Article
- Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective.European journal of nuclear medicine and molecular imaging · 2025Article
- Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Biomarker-driven molecular imaging probes in radiotherapy.Theranostics · 2024Review
Corrections and comments
- Update of
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeCancer treatment with alpha-emitter-based radioligand therapies (α-RLTs) demonstrates promising tumor responses. Radiolabeled peptides are filtered through glomeruli, followed by potential reabsorption of a fraction by proximal tubules, which may cause acute kidney injury (AKI) and chronic kidney disease (CKD). Because tubular cells are considered the primary site of radiopeptides' renal reabsorption and potential injury, the current use of kidney biomarkers of glomerular functional loss limits the evaluation of possible nephrotoxicity and its early detection. This study aimed to investigate whether urinary secretion of tubular injury biomarkers could be used as an additional non-invasive sensitive diagnostic tool to identify unrecognizable tubular damage and risk of long-term α-RLT nephrotoxicity.
methodsA bifunctional cyclic peptide, melanocortin 1 ligand (MC1L), labeled with [
resultsBiodistribution analysis identified [
conclusionUrine NGAL secretion could be a potential early diagnostic tool to identify unrecognized tubular damage and predict long-term α-RLT-related nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.